Journal
CANCER CELL
Volume 15, Issue 2, Pages 148-159Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2008.12.017
Keywords
-
Categories
Funding
- National Institutes of Health [R01 CA103866, R01 A104389, R01 CA107166, K99 CA1296613-01A1]
- W.M. Keck Foundation
- Damon Runyon Cancer Research Foundation
- Leukemia & Lymphoma Society
Ask authors/readers for more resources
mTOR complex 2 (mTORC2) contains the mammalian target of rapamycin (mTOR) kinase and the Rictor regulatory protein and phosphorylates Akt. Whether this function of mTORC2 is critical for cancer progression is unknown. Here, we show that transformed human prostate epithelial cells lacking PTEN require mTORC2 to form tumors when injected into nude mice. Furthermore, we find that Rictor is a haploinsufficient gene and that deleting one copy protects Pten heterozygous mice from prostate cancer. Finally, we show that the development of prostate cancer caused by Pten deletion specifically in prostate epithelium requires mTORC2, but that for normal prostate epithelial cells, mTORC2 activity is nonessential. The selective requirement for mTORC2 in tumor development suggests that mTORC2 inhibitors may be of substantial clinical utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available